Investigating the Bioavailability of Broccoli Extract Supplements

Purpose

The goal of this clinical trial is to compare how much glucoraphanin and sulforaphane from 3 different versions of broccoli extract supplements is absorbed into the body and excreted in urine. This study involves generally healthy adults age 18-60 years. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. Participants will: - consume 3 different versions of broccoli extract supplements (glucoraphanin will range from 35-70 mg) - complete 3 separate 24 hour study cycles - submit blood and urine samples for 24 hours - follow diet restrictions (no cruciferous vegetables or condiments or phytochemical/herbal supplements for 1 week prior to and during each study cycle)

Condition

  • Diet, Healthy

Eligibility

Eligible Ages
Between 18 Years and 60 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy adults, 18-60 years of age - Willing to stop taking herbal and phytochemical (plant-based extract or phytochemical) supplements for 1 week prior to and during each study cycle - Willing to stop cruciferous vegetable intake 1 week prior to and during each study cycle - Must be able to give written informed consent

Exclusion Criteria

  • Body Mass Index (BMI) <18.5 or >30.0 kg/m2 - Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past three months - Pregnancy, breastfeeding, or planning to become pregnant before completing the study - Engaging in vigorous exercise more than 7 hours per week - Have a significant acute or chronic illness such as cardiovascular disease, kidney or liver disease, diabetes, thyroid disorder, or radiation or chemotherapy treatment for cancer within the past five years - Use of medications to control cholesterol (e.g. statins, cholestyramine) or fat absorption (e.g. orlistat) - Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedure (e.g. cholecystectomy) or disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis) - Allergic to broccoli, moringa, mustard, or maitake mushrooms - Weighs less than 110 pounds - Diagnosis of sickle cell disease

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Basic Science
Masking
Double (Participant, Outcomes Assessor)
Masking Description
Participants will be blinded to the dose of glucoraphanin in each arm. Study staff analyzing samples will be blinded to treatment group.

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
35 mg glucoraphanin
Participants will swallow by mouth 1 tablet of Avmacol Extra Strength with coating.
  • Dietary Supplement: Avmacol Extra Strength with coating - 1 tablet
    Participants will swallow by mouth 1 tablet Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)
Active Comparator
60 mg glucoraphanin
Participants will chew and swallow by mouth 2 tablets of Avmacol chewable wafers (30 mg glucoraphanin each)
  • Dietary Supplement: Avmacol chewable wafer - 2 tablets
    Participants will chew and swallow by mouth 2 wafers Avmacol chewable wafers (30 mg glucoraphanin per wafer)
Active Comparator
70 mg glucoraphanin
Participants will swallow by mouth 2 tablets of Avmacol Extra Strength with coating (35 mg glucoraphanin each)
  • Dietary Supplement: Avmacol Extra Strength with coating - 2 tablets
    Participants will swallow by mouth 2 tablets Avamacol Extra Strength with coating (35 mg glucoraphanin per tablet)

Recruiting Locations

Oregon State University
Corvallis, Oregon 97331
Contact:
Sandra Uesugi, RN, BSN, MS
541-737-3594
sandra.uesugi@oregonstate.edu

More Details

Status
Recruiting
Sponsor
Oregon State University

Study Contact

Emily Ho, PhD
541-737-9559
emily.ho@oregonstate.edu

Detailed Description

This study aims to compare the bioavailability of 3 different versions of a broccoli extract supplement in generally healthy adults age 18-60 years who do not smoke or are not pregnant/lactating. The supplements contain glucoraphanin and myrosinase enzyme, both naturally occurring in cruciferous vegetables. Once ingested, glucoraphanin is converted to the bioactive compound sulforaphane, which is thought to have numerous health benefits, including cancer prevention. The amount of glucoraphanin that subjects will take will range from 35-70 mg. Glucoraphanin, sulforaphane, and sulforaphane metabolites will be measured in plasma and urine for 24 hours (plasma: 0, 0.5, 1, 2, 4, 8, and 24 hours after supplement consumption; urine: 0-2, 2-4, 4-8, and 8-24 hour after supplement consumption).